2cureX
2.29 SEK
+1.78 %
Less than 1K followers
2CUREX
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
+1.78 %
+110.09 %
+66.55 %
+345.53 %
+62.41 %
+282.94 %
-65.62 %
-87.83 %
-69.89 %
2cureX is a Danish-based biotech company with subsidiary in Hamburg, Germany. The company has made a special sensitivity test, IndiTreat, for oncology clinics that is focused on improving the outcome for cancer patients by improving the efficiency of the individual cancer treatment. IndiTreat uses a biopsy from the individual cancer patient to measure and predict the likely outcome of different available treatments, thereby assisting oncologists to choose the most effective treatment for the individual patient.
Read moreMarket cap
73.06M SEK
Turnover
829.68K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
25/6
2026
General meeting '26
27/8
2026
Interim report Q2'26
4/3
2027
Annual report '26
All
Press releases
3rd party
ShowingAll content types
2cureX AB (publ) publishes Interim Report for the Second Half of 2025
CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools